Brief: Calcimedica Announces Clinical Development Of Auxora May Proceed Following FDA Review Of Kourage Trial Interim Safety Data
24/06/2026 12:26
BRIEF-Calcimedica Announces Clinical Development Of Auxora May Proceed Following FDA Review Of Kourage Trial Interim Safety Data June 24 (Reuters) - CalciMedica Inc CALC.O:
CALCIMEDICA ANNOUNCES CLINICAL DEVELOPMENT OF AUXORA MAY PROCEED FOLLOWING FDA REVIEW OF KOURAGE TRIAL INTERIM SAFETY DATA
CALCIMEDICA - FDA REVIEW ALLOWS CALCIMEDICA TO CONTINUE DOSING AUXORA IN KOURAGE TRIAL
CALCIMEDICA - FDA PROVIDES NO COMMENTS, CALCIMEDICA TO CONTINUE AUXORA DEVELOPMENT ACROSS INDICATIONS
CALCIMEDICA - EXPECTS FDA FEEDBACK ON AUXORA PANCREATITIS PROGRAM IN Q3 2026
Source text: ID:nPn1Z4LB7a
Further company coverage: CALC.O
((Reuters.Briefs@thomsonreuters.com;))